Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

p>A breakdown of these entities' revenues by therapeutic area may be found in Appendix V.

Important noticeThe Proposal is subject to the following pre-conditions, which will need to be satisfied or waived prior to any announcement of the Possible Offer under Rule 2.5 of the Irish Takeover Rules:

  (i)
being granted access to and completion of satisfactory due diligence into the business of Elan, including management meetings;

 (ii)
no acquisitions, dispositions, restructuring activities, debt refinancing, stock buybacks or other extraordinary transactions by Elan apart from the completion of the Tysabri Transaction;

(iii)
the Tysabri Transaction shall have closed and the terms shall not have been amended or altered in any material respect from the terms announced on February 6, 2013;

(iv)
unanimous recommendation of the Possible Offer, if made, by the directors of Elan;

 (v)
each of the directors of Elan giving firm irrevocable undertakings to accept the Possible Offer, if made, or to vote in favour of the scheme of arrangement (as applicable) in respect of all the Elan Stock in which they have an interest;

(vi)
the entry into an expense reimbursement agreement in a form acceptable to Royalty Pharma in respect of an amount equal to the maximum allowable under the terms of the Irish Takeover Rules and the financial advisor to Elan confirming to the Irish Takeover Panel that such agreement is in the best interests of Elan's Shareholders;

(vii)
Elan's assistance, as appropriate, in obtaining support from its major institutional shareholders for the Possible Offer, if made; and

(viii)
execution of an appropriate implementation agreement to govern the conduct of a scheme of arrangement if the transaction is to be structured in that manner.

Royalty Pharma reserves the right to waive any or all of the pre-conditions described in this announcement and to implement
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... Lawrence, MA (PRWEB) August 28, 2014 “This ... single test to screen from 0 to 150 ppb,” said ... test is a significant benefit to plant owners and USDA-GIPSA ... corn and other commodities. Testing can take place in a ... Not only can the plant test the feed and grain ...
(Date:8/28/2014)... BOSTON , Aug. 28, 2014  Next month, executives ... at three key industry events beginning with Patient-Centered Clinical ... Hotel in Boston , September 4-5. Patient ... , and Aaron Fleishman will share insights on ... how a variety of tactics – from media to mobile ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... Funding Milestone Continues Progress at Seneca, Illinois ... ... NBF ) announced today that it has satisfied the conditions ... million,senior secured credit facility with WestLB AG, one of the world,s ...
... Phase 2b Trial Expected to Begin in the ... 4 Mpex Pharmaceuticals, Inc. today,announced that the ... Products Development has granted Mpex orphan drug designation ... pulmonary,infections due to Pseudomonas aeruginosa and other bacteria ...
... the Chinese Pharmaceutical ... CHENGDU, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, ... and,supplier of modernized traditional Chinese medicine ("TCM") based ... members:,Professor Zunjian Zhang, Ph.D., Professor Jianping Hou, Ph.D. ...
Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 2Tianyin Pharmaceutical Appoints Three New Independent Board Members 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 4
(Date:8/28/2014)... A free mobile app called TX Invasives is now ... The University of Texas at Austin for identifying harmful ... , Invasive species in the United States cause about ... they destroy agricultural crops, clog waterways, kill native plants ... TX Invasives app for reporting where invasive species occur, ...
(Date:8/28/2014)... German . ... to a striking pattern of blue stripes alternating with golden ... cells, and yellow cells emerge during growth in the skin ... mosaic to compose the characteristic colour pattern. ,While ... interact to form proper stripes, the embryonic origin of the ...
(Date:8/28/2014)... 2014) Researchers at the University of Minnesota have ... (FSHD) to be used for muscle regeneration research as ... for FSHD. , The research is published in the ... , There is no treatment for FSHD, which is ... of muscular dystrophy. FSHD is an unusual genetic disorder ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3UMN researchers find animal model for understudied type of muscular dystrophy 2
... The tummy,s taste for red wine with red meat , ... happens when red wine meets red meat? If the rendezvous ... bounty of healthful chemical compounds may thwart formation of harmful ... study, which reinforces the benefits of consuming wine and other ...
... closer to understanding the recent demise of billions of honey ... a common bee virus. Deformed wing virus (DWV) is passed ... parasitic mite called Varroa destructor when it feeds. However, research ... General Virology suggests that the virus does not replicate ...
... of Crohn,s disease researchers has combined data from ... variants associated with the inflammatory bowel disorder, bringing ... Several of these are involved with the ... evidence that disruptions in a process called autophagy ...
Cached Biology News:American Chemical Society's Weekly PressPac -- June 25, 2008 2American Chemical Society's Weekly PressPac -- June 25, 2008 3American Chemical Society's Weekly PressPac -- June 25, 2008 4American Chemical Society's Weekly PressPac -- June 25, 2008 5American Chemical Society's Weekly PressPac -- June 25, 2008 6American Chemical Society's Weekly PressPac -- June 25, 2008 7American Chemical Society's Weekly PressPac -- June 25, 2008 8American Chemical Society's Weekly PressPac -- June 25, 2008 9Bee disease a mystery 2International team identifies 21 new genetic risk factors for Crohn's disease 2
...
Red Standard is sodium salt of resorufin....
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: